Cosmos Health acquires 10 generic drug portfolio for $3.5M from related party

Cosmos Health Inc.

Acquired licenses/rights to 10 generic drugs from related party for €3.2M ($3.5M).
Drugs target diabetes, cholesterol, respiratory, cardiac conditions and more.
Manufacturing to occur at Cosmos' wholly-owned subsidiary Cana Laboratories.
Global generic drugs market valued at $411.99B in 2022, projected to $613.34B by 2030.
CEO says acquisition supports transition to full-fledged pharmaceutical company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.